[Pharmacological Treatment for Restless Legs Syndrome].

Keisuke Suzuki, Tomohiro Tsuchiya, Koichi Hirata

Other Brain and nerve = Shinkei kenkyu no shinpo 2023

<\/script>\n

`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D37194531'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Abstract

Restless legs syndrome (RLS) is a neurological disorder that causes insomnia and daytime functional disability due to an urge to move the legs usually accompanied by uncomfortable sensations. Non-pharmacologic treatment includes regular sleep habits and exercise. Iron supplementation is indicated for patients with low serum ferritin levels. Antidepressants, antihistaminergics, and dopamine antagonists should be reduced or discontinued because they induce RLS symptoms. Dopamine agonists and alpha 2-delta ligands are the first-line pharmacological treatments for RLS.

TL;DR

Treatment for restless legs syndrome includes regular sleep habits and exercise, and dopamine agonists and alpha 2-delta ligands are the first-line pharmacological treatments for RLS.

Used In Evidence Reviews

A Iron for Restless Leg Syndrome

[Pharmacological Treatment for Restless Legs Syndrome].

Embed This Widget

Abstract

TL;DR

Used In Evidence Reviews

Similar Papers

Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).

Restless legs syndrome and pregnancy.

Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice.

Restless legs syndrome: pathophysiology, clinical presentation and management.

Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).

Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.